NASDAQ
2.60USD
+0.02 (+0.78%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
24.1M
P/E
—
EPS
—
Beta
-4.31
52W range
2.13-11.25
Day range
2.60–2.67
Open
2.60
Prev close
2.58
Volume
121.7K
Avg volume
5.6M
Dividend
0.00
IPO
2008-05-23
https://www.globenewswire.com/news-release/2026/08/04/3338085/0/en/CervoMed-Announces-Neflamapimod-Awarded-Innovation-Passport-Designation-Under-the-UK-Innovative-Licensing-and-Access-Pathway-ILAP-for-Treatment-of-Dementia-with-Lewy-Bodies-DLB.html · 8/4/2026+0.80
https://www.globenewswire.com/news-release/2026/07/06/3322335/0/en/CervoMed-Showcases-Leadership-in-Advancing-the-Treatment-and-Care-of-Dementia-with-Lewy-Bodies-at-the-Alzheimer-s-Association-International-Conference-AAIC-2026.html · 7/6/2026+0.80
https://www.globenewswire.com/news-release/2026/06/12/3310989/0/en/CervoMed-to-Participate-in-the-H-C-Wainwright-7th-Annual-Neuro-Perspectives-Expert-Summit.html · 6/12/2026+0.20
https://www.prnewswire.com/news-releases/gigabyte-presenta-en-computex-2026-sus-elegantes-configuraciones-de-pc-de-las-series-stealth-y-wood-302792465.html · 6/5/2026
https://www.prnewswire.com/news-releases/gigabyte-prasentiert-elegante-stealth--und-wood-pc-systeme-auf-der-computex-2026-302792463.html · 6/5/2026+0.40
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
